American Association for Cancer Research
Browse
ccr-22-1768_supplemental_table_3_suppts3.docx (120.37 kB)

Supplemental Table 3 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit

Download (120.37 kB)
journal contribution
posted on 2023-04-01, 00:24 authored by Marco A. Mascarella, Tolani F. Olonisakin, Purva Rumde, Varun Vendra, Melonie A. Nance, Seungwon Kim, Mark W. Kubik, Shaum S. Sridharan, Robert L. Ferris, Moon J. Fenton, Daniel R. Clayburgh, James P. Ohr, Sonali C. Joyce, Malabika Sen, James G. Herman, Jennifer R. Grandis, Dan P. Zandberg, Umamaheswar Duvvuri

Comparison of clinical to pathologic stage migration between patients enrolled in 1 of 4 window trials compared to a second control group

Funding

U.S. Department of Veterans Affairs (VA)

National Institute of Dental and Craniofacial Research (NIDCR)

History

ARTICLE ABSTRACT

Neoadjuvant targeted therapy provides a brief, preoperative window of opportunity that can be exploited to individualize cancer care based on treatment response. We investigated whether response to neoadjuvant therapy during the preoperative window confers survival benefit in patients with operable head and neck squamous cell carcinoma (HNSCC). A pooled analysis of treatment-naïve patients with operable HNSCC enrolled in one of three clinical trials from 2009 to 2020 (NCT00779389, NCT01218048, NCT02473731). Neoadjuvant regimens consisted of EGFR inhibitors (n = 83) or anti-ErbB3 antibody therapy (n = 9) within 28 days of surgery. Clinical to pathologic stage migration was compared with disease-free survival (DFS) and overall survival (OS) while adjusting for confounding factors using multivariable Cox regression. Circulating tumor markers validated in other solid tumor models were analyzed. 92 of 118 patients were analyzed; all patients underwent surgery following neoadjuvant therapy. Clinical to pathologic downstaging was more frequent in patients undergoing neoadjuvant targeted therapy compared with control cohort (P = 0.048). Patients with pathologic downstage migration had the highest OS [89.5%; 95% confidence interval (CI), 75.7–100] compared with those with no stage change (58%; 95% CI, 46.2–69.8) or upstage (40%; 95% CI, 9.6–70.4; P = 0.003). Downstage migration remained a positive prognostic factor for OS (HR, 0.22; 95% CI, 0.05–0.90) while adjusting for measured confounders. Downstage migration correlated with decreased circulating tumor markers, SOX17 and TAC1 (P = 0.0078). Brief neoadjuvant therapy achieved pathologic downstaging in a subset of patients and was associated with significantly better DFS and OS as well as decreased circulating methylated SOX17 and TAC1.

Usage metrics

    Clinical Cancer Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC